|
DE19624659A1
(de)
*
|
1996-06-20 |
1998-01-08 |
Klinge Co Chem Pharm Fab |
Neue Pyridylalken- und Pyridylalkinsäureamide
|
|
DE19756236A1
(de)
*
|
1997-12-17 |
1999-07-01 |
Klinge Co Chem Pharm Fab |
Neue piperazinylsubstituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
|
|
DE19756212A1
(de)
*
|
1997-12-17 |
1999-07-01 |
Klinge Co Chem Pharm Fab |
Neue, mit einem cyclischen Imid substituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
|
|
DE19756235A1
(de)
*
|
1997-12-17 |
1999-07-01 |
Klinge Co Chem Pharm Fab |
Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide
|
|
DE19756261A1
(de)
*
|
1997-12-17 |
1999-07-01 |
Klinge Co Chem Pharm Fab |
Neue arylsubstituierte Pyridylalkan-, alken- und alkincarbonsäureamide
|
|
DE19818044A1
(de)
*
|
1998-04-22 |
1999-10-28 |
Klinge Co Chem Pharm Fab |
Verwendung von Vitamin-PP-Verbindungen
|
|
BR9915403A
(pt)
*
|
1998-11-17 |
2001-08-14 |
Hoffmann La Roche |
Antagonistas receptores iii de 4-aroil-piperidin-ccr-3
|
|
EP1031564A1
(en)
*
|
1999-02-26 |
2000-08-30 |
Klinge Pharma GmbH |
Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy
|
|
US6432432B1
(en)
|
1999-03-05 |
2002-08-13 |
Arch Chemicals, Inc. |
Chemical method of making a suspension, emulsion or dispersion of pyrithione particles
|
|
CO5180550A1
(es)
|
1999-04-19 |
2002-07-30 |
Smithkline Beecham Corp |
Inhibidores de fab i
|
|
CO5370679A1
(es)
|
1999-06-01 |
2004-02-27 |
Smithkline Beecham Corp |
Inhibidores fab 1
|
|
US6730684B1
(en)
|
1999-10-08 |
2004-05-04 |
Affinium Pharmaceuticals, Inc. |
Fab I inhibitors
|
|
PE20010635A1
(es)
|
1999-10-08 |
2001-08-15 |
Smithkline Beecham Corp |
Inhibidores de fab i utiles para el tratamiento de infecciones bacterianas
|
|
US6762201B1
(en)
|
1999-10-08 |
2004-07-13 |
Affinium Pharmaceuticals, Inc. |
Fab I inhibitors
|
|
DK1560584T3
(da)
|
2001-04-06 |
2009-05-18 |
Affinium Pharm Inc |
Fab I inhibitorer
|
|
FR2823975B1
(fr)
*
|
2001-04-27 |
2003-05-30 |
Sanofi Synthelabo |
Nouvelle utilisation de pyridoindolone
|
|
EP1348434A1
(en)
*
|
2002-03-27 |
2003-10-01 |
Fujisawa Deutschland GmbH |
Use of pyridyl amides as inhibitors of angiogenesis
|
|
PT1599468E
(pt)
|
2003-01-14 |
2008-01-14 |
Arena Pharm Inc |
Derivados de arilo e heteroarilo 1,2,3.-trissubstituídos comomoduladores do metabolismo, e profilaxia e tratamento dedesordens relacionadas tais como diabetes e hiperglicemia
|
|
EP2583678A3
(en)
|
2004-06-24 |
2013-11-13 |
Novartis Vaccines and Diagnostics, Inc. |
Small molecule immunopotentiators and assays for their detection
|
|
DOP2006000010A
(es)
|
2005-01-10 |
2006-07-31 |
Arena Pharm Inc |
Procedimiento para preparar eteres aromáticos
|
|
US20110045065A1
(en)
*
|
2005-07-11 |
2011-02-24 |
Ashok Vasantray Vyas |
Substance having antioxidant, geroprotective and anti-ischemic activity and method for the preparation thereof
|
|
US8067457B2
(en)
|
2005-11-01 |
2011-11-29 |
Millennium Pharmaceuticals, Inc. |
Compounds useful as antagonists of CCR2
|
|
WO2007053499A2
(en)
|
2005-11-01 |
2007-05-10 |
Millennium Pharmaceuticals, Inc. |
Compounds useful as antagonists of ccr2
|
|
WO2008009122A1
(en)
|
2006-07-20 |
2008-01-24 |
Affinium Pharmaceuticals, Inc. |
Acrylamide derivatives as fab i inhibitors
|
|
WO2008026018A1
(en)
|
2006-09-01 |
2008-03-06 |
Topotarget Switzerland Sa |
New method for the treatment of inflammatory diseases
|
|
WO2008098374A1
(en)
|
2007-02-16 |
2008-08-21 |
Affinium Pharmaceuticals, Inc. |
Salts, prodrugs and polymorphs of fab i inhibitors
|
|
EP2098231A1
(en)
|
2008-03-05 |
2009-09-09 |
Topotarget Switzerland SA |
Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury
|
|
CN102123988B
(zh)
|
2008-06-24 |
2013-08-14 |
顶标公司 |
作为烟酰胺抑制剂的方酸衍生物
|
|
RU2011111728A
(ru)
|
2008-08-29 |
2012-10-10 |
Топотаргет А/С (Dk) |
Новые производные мочевины и тиомочевины
|
|
CN102421754B
(zh)
*
|
2009-05-12 |
2013-11-27 |
北京世桥生物制药有限公司 |
丙烯酰胺类衍生物及其制备药物的用途
|
|
CA2768338A1
(en)
|
2009-07-17 |
2011-01-20 |
Topotarget A/S |
Method for predicting the utility of administering nicotinic acid or a precursor or prodrug thereof to reduce the severity of side-effects of cancer treatment with nicotinamide phosphoribosyltransferase inhibitors
|
|
WO2011121055A1
(en)
|
2010-03-31 |
2011-10-06 |
Topotarget A/S |
Pyridinyl derivatives comprising a cyanoguanidine or squaric acid moiety
|
|
JP5881705B2
(ja)
|
2010-09-03 |
2016-03-09 |
フォーマ ティーエム， エルエルシー． |
Ｎａｍｐｔの阻害のための新規化合物及び組成物
|
|
KR20130114119A
(ko)
|
2010-09-03 |
2013-10-16 |
포르마 티엠, 엘엘씨. |
Ｎａｍｐｔ의 억제를 위한 신규 화합물 및 조성물
|
|
CN106986856A
(zh)
|
2010-09-03 |
2017-07-28 |
福马Tm有限责任公司 |
作为用于治疗疾病诸如癌症的nampt抑制剂的4‑{[(吡啶‑3‑基‑甲基)氨基羰基]氨基}苯‑砜衍生物
|
|
JP5941916B2
(ja)
|
2010-09-22 |
2016-06-29 |
アリーナ ファーマシューティカルズ， インコーポレイテッド |
Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置
|
|
AR083200A1
(es)
*
|
2010-09-29 |
2013-02-06 |
Intervet Int Bv |
Compuestos de n-heteroarilo
|
|
WO2012067963A1
(en)
|
2010-11-15 |
2012-05-24 |
Abbott Laboratories |
Nampt inhibitors
|
|
AR083855A1
(es)
|
2010-11-15 |
2013-03-27 |
Abbott Lab |
Inhibidores de nampt y rock
|
|
AU2011367222B2
(en)
|
2011-05-04 |
2017-04-13 |
Forma Tm, Llc |
Novel compounds and compositions for the inhibition of NAMPT
|
|
TW201245188A
(en)
|
2011-05-09 |
2012-11-16 |
Forma Therapeutics Inc |
Novel compounds and compositions for the inhibition of NAMPT
|
|
PL2736887T3
(pl)
|
2011-07-29 |
2018-03-30 |
Karyopharm Therapeutics, Inc. |
Modulatory transportu jądrowego zawierające ugrupowanie hydrazydu i ich zastosowania
|
|
PT2858991T
(pt)
|
2012-05-09 |
2018-12-17 |
Biogen Ma Inc |
Moduladores do transporte nuclear e usos dos mesmos
|
|
US8975398B2
(en)
|
2012-05-11 |
2015-03-10 |
Abbvie Inc. |
NAMPT inhibitors
|
|
EP2852585A1
(en)
|
2012-05-11 |
2015-04-01 |
AbbVie Inc. |
Nampt inhibitors
|
|
CA2870566A1
(en)
|
2012-05-11 |
2013-11-14 |
Abbvie Inc. |
Thiazolecarboxamide derivatives for use as nampt inhibitors
|
|
MX2014013734A
(es)
|
2012-05-11 |
2015-06-10 |
Abbvie Inc |
Inhibidores de nampt.
|
|
NZ702695A
(en)
|
2012-06-19 |
2015-10-30 |
Debiopharm Int Sa |
Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
|
|
US9938258B2
(en)
|
2012-11-29 |
2018-04-10 |
Karyopharm Therapeutics Inc. |
Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof
|
|
WO2014144772A1
(en)
|
2013-03-15 |
2014-09-18 |
Karyopharm Therapeutics Inc. |
Methods of promoting wound healing using crm1 inhibitors
|
|
RS58581B1
(sr)
|
2013-06-21 |
2019-05-31 |
Karyopharm Therapeutics Inc |
1,2,4-triazoli kao modulatori jedarnog transporta i njihova primena
|
|
US9856241B2
(en)
*
|
2013-07-03 |
2018-01-02 |
Karyopharm Therapeutics Inc. |
Substituted benzofuranyl and benzoxazolyl compounds and uses thereof
|
|
WO2015042414A1
(en)
|
2013-09-20 |
2015-03-26 |
Karyopharm Therapeutics Inc. |
Multicyclic compounds and methods of using same
|
|
EP3055304A1
(en)
*
|
2013-10-09 |
2016-08-17 |
Eli Lilly and Company |
Novel pyridyloxyacetyl tetrahydroisoquinoline compounds useful as nampt inhibitors
|
|
CN106661013A
(zh)
|
2014-07-23 |
2017-05-10 |
奥瑞基尼探索技术有限公司 |
用作nampt抑制剂的4，5‑二氢异噁唑衍生物
|
|
CN111484483B
(zh)
|
2014-08-15 |
2023-05-26 |
卡尔约药物治疗公司 |
赛灵克斯的多晶型物
|
|
PL3242666T3
(pl)
|
2015-01-06 |
2025-02-17 |
Arena Pharmaceuticals, Inc. |
Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
|
|
CN104447483B
(zh)
*
|
2015-01-13 |
2016-07-27 |
佛山市赛维斯医药科技有限公司 |
含苯胺和二烯金刚烷结构的化合物、其制备方法和用途
|
|
CN104447484B
(zh)
*
|
2015-01-13 |
2016-06-08 |
佛山市赛维斯医药科技有限公司 |
含烷氧苯基和二烯金刚烷结构的化合物、其制备方法和用途
|
|
CN104447486B
(zh)
*
|
2015-01-13 |
2016-06-01 |
佛山市赛维斯医药科技有限公司 |
二烯氟代金刚烷类化合物、其制备方法和用途
|
|
DK3310760T3
(da)
|
2015-06-22 |
2022-10-24 |
Arena Pharm Inc |
Krystallinsk L-argininsalt af (R)-2-(7-(4-cyclopentyl-3-(trifluormethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3- yl)eddikesyre til anvendelse ved S1P1-receptor-associerede lidelser
|
|
JP2018528196A
(ja)
|
2015-08-18 |
2018-09-27 |
カリオファーム セラピューティクス，インコーポレイテッド |
癌の治療のための（ｓ，ｅ）−３−（６−アミノピリジン−３−イル）−ｎ−（（５−（４−（３−フルオロ−３−メチルピロリジン−１−カルボニル）フェニル）−７−（４−フルオロフェニル）ベンゾフラン−２−イル）メチル）アクリルアミド
|
|
TW201720802A
(zh)
*
|
2015-09-15 |
2017-06-16 |
艾森伯利生物科學公司 |
B型肝炎核心蛋白質調節劑
|
|
WO2017117535A1
(en)
|
2015-12-31 |
2017-07-06 |
Karyopharm Therapeutics Inc. |
Nuclear transport modulators and uses thereof
|
|
WO2017117447A1
(en)
|
2015-12-31 |
2017-07-06 |
Karyopharm Therapeutics Inc. |
Multicyclic compounds and uses thereof
|
|
US10526295B2
(en)
|
2015-12-31 |
2020-01-07 |
Karyopharm Therapeutics Inc. |
Nuclear transport modulators and uses thereof
|
|
ES2842443T3
(es)
|
2016-02-26 |
2021-07-14 |
Debiopharm Int Sa |
Medicamento para el tratamiento de infecciones del pie diabético
|
|
EP3279192A1
(en)
|
2016-08-05 |
2018-02-07 |
Centre Hospitalier Universitaire Vaudois (CHUV) |
Piperidine derivatives for use in the treatment of pancreatic cancer
|
|
WO2018086703A1
(en)
|
2016-11-11 |
2018-05-17 |
Bayer Pharma Aktiengesellschaft |
Dihydropyridazinones substituted with phenylureas
|
|
US11602530B2
(en)
|
2016-11-28 |
2023-03-14 |
Biogen Ma Inc. |
CRM1 inhibitors for treating epilepsy
|
|
CN107827897A
(zh)
*
|
2017-10-23 |
2018-03-23 |
青岛大学 |
一种手性七元螺环吲哚酮类化合物的合成方法
|
|
CA3089754A1
(en)
|
2018-01-31 |
2019-08-08 |
Bayer Aktiengesellschaft |
Antibody drug conjugates (adcs) with nampt inhibitors
|
|
CN108558840B
(zh)
*
|
2018-06-04 |
2020-11-06 |
上海交通大学 |
水溶性氮杂α-萘黄酮类化合物及其制备方法和医药用途
|
|
BR112020024762A2
(pt)
|
2018-06-06 |
2021-03-23 |
Arena Pharmaceuticals, Inc. |
métodos de tratamento de condições relacionadas ao receptor s1p1
|
|
IL285204B2
(en)
|
2019-02-14 |
2025-02-01 |
Debiopharm Int Sa |
Formulation of apavicin, method for its preparation
|
|
EP3982975A1
(en)
|
2019-06-14 |
2022-04-20 |
Debiopharm International SA |
Afabicin for use for treating bacterial infections involving biofilm
|
|
WO2021013693A1
(en)
|
2019-07-23 |
2021-01-28 |
Bayer Pharma Aktiengesellschaft |
Antibody drug conjugates (adcs) with nampt inhibitors
|
|
KR20220110744A
(ko)
|
2019-11-06 |
2022-08-09 |
레미디 플랜, 인크. |
암 줄기 세포를 표적화하는 암 치료
|
|
JP2024518089A
(ja)
|
2021-05-13 |
2024-04-24 |
リメディー プラン，インコーポレーテッド |
Ｎａｍｐｔ阻害剤とその使用
|